RNS Number : 5357Y
Fusion Antibodies PLC
30 March 2026

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse (amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

30 March 2026

Fusion Antibodies plc

("**Fusion**" or the **"Company**")

Antibody IP transfer agreement

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has entered into an agreement to transfer the ownership of certain background intellectual property ("**IP**") owned by Fusion (the "**IP Transfer Agreement**") to an existing client, Finn Therapeutics Ltd (the "**Client**"). The IP Transfer Agreement covers a novel rabbit antibody.

The IP Transfer Agreement results in a one-off payment to Fusion of £250,000 for the IP and related reach through to the humanized sequences. The Client is pleased to take ownership of the background IP as this is expected to streamline its fundraising activities and the Company has agreed to tailored payment terms with the Client to allow for these fundraising activities.

The Client has been working closely with Fusion, placing a series of projects with the Company and has indicated it intends to continue to do so as the development of the humanised antibody progresses. The entire IP Transfer Agreement fee payable to Fusion will be recognised in the current financial year ending 31 March 2026.

Adrian Kinkaid, CEO of Fusion, said: *"We are delighted with the progress that has been made with this molecule and its derivatives. We recognise the challenging investment conditions many small biotechnology companies face at this time and are keen to support our clients with creative deal solutions such as this. We look forward to working with Finn Therapeutics as they progress this project and bring better antibodies to the clinic more rapidly. The project highlights the strong reputation that Fusion has as the collaborative research partner of choice for antibody therapeutics."*

Paul Kerr, CEO of Finn Therapeutics commented: *"Acquiring full ownership of this background IP is a significant de-risking event that streamlines our fundraising and accelerates our path to clinical entry. As an asset-centric company; this move allows us to efficiently leverage our development partners and we look forward to continuing our relationship with Fusion, as we work to redefine the standard of care with this first-in-class oncology candidate."*

Navigate to our Interactive Investor hub here: https://investorhub.fusionantibodies.com/. Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.

Enquiries:

Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR

Fusion Antibodies interactive investor hub https://investorhub.fusionantibodies.com/

Allenby Capital Limited Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Shard Capital Partners LLP
Damon Heath (Joint Broker) Tel: +44 (0) 207 186 9952

Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRPPUWPWUPQGUB